Project Grant R21AI193612
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$423K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This federal Project Grant award of $232,073.00, provided by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to investigate the dynamics between the fungal pathogen Cryptococcus neoformans (CN) and microglia cells in the context of HIV co-infection. The research aims to explore the impact of CN's replicative aging on its survival and virulence within the host, particularly in the cerebrospinal...
This federal Project Grant award of $616,588 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research by The Regents of the University of California, San Francisco (UCSF) to exploit a high-precision phenotypic map to illuminate environmental sensing mechanisms of the fungal pathogen Cryptococcus neoformans, which causes fungal meningitis. The research aims to 1) dissect the function of new components of key...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $773,053 to Washington University to conduct research on understanding the synthesis of beta-1,6-glucan, a key component of the cryptococcal cell wall. The research aims to elucidate the role of the GGT2 glycosyltransferase protein in beta-1,6-glucan formation and identify the full machinery required for this process...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on exploring the genetic basis of two pathogenesis-relevant traits in the Cryptococcus fungal genus: thermotolerance and azole drug resistance. The $443,944 award, with a performance period from August 2024 to July 2029, will employ high-throughput genetic approaches to characterize genome-wide...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $158,433 to Clemson University to conduct research on the metabolic determinants of carbon dioxide tolerance in the pathogenic fungus Cryptococcus neoformans. The research aims to identify the specific mechanisms that allow Cryptococcus to tolerate high levels of carbon dioxide, which is a key virulence trait enabling the fungus to cause deadly...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $515,875 over approximately 5 years to the University of Florida to conduct research on the mechanisms underlying Cryptococcus neoformans-induced meningoencephalitis and neurotoxicity in a CD4 T cell-deficient mouse model. The key objectives are to: (1) determine how the Cryptococcus neoformans capsular...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $782,178 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Research Foundation for the State University of New York, doing business as Stony Brook University. The grant supports research to develop novel antifungal inhibitors targeting the sterylglucosidase enzymes SGL1 and SGLA, which are essential for the pathogenicity of the fungal pathogens Cryptococcus neoformans and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $170,000 research project by Prokaryotics Incorporated to develop novel antifungal therapeutics. The goal is to perform structural biology studies on the GPI ethanolamine phosphate transferase enzyme MCD4, which is a promising target for new antifungal drug candidates. The research aims to obtain...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $857,215 to HMH Hospitals Corporation (doing business as Hackensack University Medical Center) to conduct research on how the fungal pathogen Candida albicans adapts to different host environments, such as the oral and systemic infection niches. The research aims to decipher how the fungal acetylome, regulated by the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $494,696 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Health Science Center at San Antonio (UTHSCSA). The grant will fund research to better understand the translational control mechanisms that allow the fungal pathogen Candida albicans to respond to host environmental stresses and undergo critical morphological changes that enable infection....